Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05361395 |
|---|---|
| Brief Title: | First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) |
| First Submitted : | April 29, 2022 |
| First Submitted that Met QC Criteria : | April 29, 2022 |
| First Posted : | May 4, 2022 |
| Last Update Submitted that Met QC Criteria : | May 9, 2024 |
| Last Update Posted : | May 10, 2024 |